Therapeutic Potential of MTOR Inhibitors for Targeting Cancer Stem Cells

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2015 Nov 27

PMID 26609914

Citations 19

Authors

Maria Giovanna Francipane

Eric Lagasse

Affiliations

Soon will be listed here.

Abstract

The mammalian target of rapamycin (mTOR) pathway is aberrantly activated in many cancer types. As the intricate network of regulatory mechanisms controlling mTOR activity is uncovered, more refined drugs are designed and tested in clinical trials. While first generation mTOR inhibitors have failed to show clinical efficacy due partly to the feedback relief of oncogenetic circuits, newly developed inhibitors show greater promise as anti-cancer agents. An effective drug must defeat the cancer stem cells (CSCs) while sparing the normal stem cells. Due to its opposing role on normal and malignant stem cells, mTOR lends itself very well as a therapeutic target. Indeed, a preferential inhibitory effect on CSCs has already been shown for some mTOR inhibitors. These results provide a compelling rationale for the clinical development of mTOR-targeted therapies.

Citing Articles

mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions.

Cosialls E, Pacreau E, Duruel C, Ceccacci S, Elhage R, Desterke C Cell Death Dis. 2023; 14(11):744.

PMID: 37968262 PMC: 10651934. DOI: 10.1038/s41419-023-06262-5.

Fate decisions of breast cancer stem cells in cancer progression.

Xu H, Zhang F, Gao X, Zhou Q, Zhu L Front Oncol. 2022; 12:968306.

PMID: 36046046 PMC: 9420991. DOI: 10.3389/fonc.2022.968306.

Identification of Prognostic Biomarkers in Patients With Malignant Rhabdoid Tumor of the Kidney Based on mTORC1 Signaling Pathway-Related Genes.

Zhanghuang C, Yao Z, Tang H, Zhang K, Wu C, Li L Front Mol Biosci. 2022; 9:843234.

PMID: 35558559 PMC: 9087638. DOI: 10.3389/fmolb.2022.843234.

Targeting Breast Cancer and Their Stem Cell Population through AMPK Activation: Novel Insights.

Uprety B, Abrahamse H Cells. 2022; 11(3).

PMID: 35159385 PMC: 8834477. DOI: 10.3390/cells11030576.

Roles Played by YY1 in Embryonic, Adult and Cancer Stem Cells.

Martinez-Ruiz G, Morales-Sanchez A, Pacheco-Hernandez A Stem Cell Rev Rep. 2021; 17(5):1590-1606.

PMID: 33728560 PMC: 8553684. DOI: 10.1007/s12015-021-10151-9.

References

Zhang J, Grindley J, Yin T, Jayasinghe S, He X, Ross J . PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature. 2006; 441(7092):518-22. DOI: 10.1038/nature04747. View

Hynes N, Boulay A . The mTOR pathway in breast cancer. J Mammary Gland Biol Neoplasia. 2006; 11(1):53-61. DOI: 10.1007/s10911-006-9012-6. View

Gupta P, Fillmore C, Jiang G, Shapira S, Tao K, Kuperwasser C . Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146(4):633-44. DOI: 10.1016/j.cell.2011.07.026. View

Sarbassov D, Guertin D, Ali S, Sabatini D . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098-101. DOI: 10.1126/science.1106148. View

Baylin S, Jones P . A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011; 11(10):726-34. PMC: 3307543. DOI: 10.1038/nrc3130. View

Huang Z, Wu Y, Zhou X, Qian J, Zhu W, Shu Y . Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review. Future Oncol. 2015; 11(11):1687-99. DOI: 10.2217/fon.15.70. View

Hoelder S, Clarke P, Workman P . Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012; 6(2):155-76. PMC: 3476506. DOI: 10.1016/j.molonc.2012.02.004. View

Akhavan D, Cloughesy T, Mischel P . mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 2010; 12(8):882-9. PMC: 2940679. DOI: 10.1093/neuonc/noq052. View

Alvero A, Montagna M, Holmberg J, Craveiro V, Brown D, Mor G . Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther. 2011; 10(8):1385-93. PMC: 3703662. DOI: 10.1158/1535-7163.MCT-11-0023. View

10.

Manning B . Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol. 2004; 167(3):399-403. PMC: 2172491. DOI: 10.1083/jcb.200408161. View

11.

Rozengurt E, Soares H, Sinnet-Smith J . Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther. 2014; 13(11):2477-88. PMC: 4222988. DOI: 10.1158/1535-7163.MCT-14-0330. View

12.

Chen C, Liu Y, Liu Y, Zheng P . mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009; 2(98):ra75. PMC: 4020596. DOI: 10.1126/scisignal.2000559. View

13.

Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X . TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126(5):955-68. DOI: 10.1016/j.cell.2006.06.055. View

14.

Rodon J, Dienstmann R, Serra V, Tabernero J . Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013; 10(3):143-53. DOI: 10.1038/nrclinonc.2013.10. View

15.

Kimura N, Tokunaga C, Dalal S, Richardson C, Yoshino K, Hara K . A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells. 2003; 8(1):65-79. DOI: 10.1046/j.1365-2443.2003.00615.x. View

16.

Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J . Rheb binds and regulates the mTOR kinase. Curr Biol. 2005; 15(8):702-13. DOI: 10.1016/j.cub.2005.02.053. View

17.

Francipane M, Lagasse E . Therapeutic potential of mTOR inhibitors for targeting cancer stem cells. Br J Clin Pharmacol. 2015; 82(5):1180-1188. PMC: 5061787. DOI: 10.1111/bcp.12844. View

18.

Chang L, Graham P, Hao J, Ni J, Bucci J, Cozzi P . Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance. Cell Death Dis. 2013; 4:e875. PMC: 3920940. DOI: 10.1038/cddis.2013.407. View

19.

Harrison D, Strong R, Sharp Z, Nelson J, Astle C, Flurkey K . Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460(7253):392-5. PMC: 2786175. DOI: 10.1038/nature08221. View

20.

Gwinn D, Shackelford D, Egan D, Mihaylova M, Mery A, Vasquez D . AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008; 30(2):214-26. PMC: 2674027. DOI: 10.1016/j.molcel.2008.03.003. View